【摘要】 食源性生物活性肽（FBP），特别是那些氨基酸残基少于10个且分子量低于1300 Da的肽，因其安全、多样化的结构和特定的生物活性而受到越来越多的关注。基于FBP的功能性食品和潜在药物的开发取决于对其构效关系（SAR）、稳定性和生物利用度特性的理解。在这篇综述中，我们基于过去五年的文献，深入概述了FBP在治疗各种疾病中的作用，包括阿尔茨海默病、高血压、2型糖尿病、肝病和炎症性肠病。随后，我们聚焦于阐明FBP的生物活性与结构特征（例如分子量、氨基酸序列和组成中特定氨基酸的存在）之间的关联，还讨论了筛选FBP的计算机模拟方法及其局限性。最后，我们总结了剂型技术的最新进展，以提高食品工业中FBP的生物利用度，从而为医疗保健应用做出贡献。更多还原

【Abstract】 Food-derived bioactive peptides(FBPs), particularly those with ten or fewer amino acid residues and a molecular weight below 1300 Da, have gained increasing attention for their safe, diverse structures and specific biological activities. The development of FBP-based functional foods and potential medications depends on understanding their structure-activity relationships(SARs), stability, and bioavailability properties. In this review, we provide an in-depth overview of the roles of FBPs in treating various diseases, including Alzheimer’s disease, hypertension, type 2 diabetes mellitus, liver diseases, and inflammatory bowel diseases, based on the literature from July 2017 to Mar. 2023. Subsequently, attention is directed toward elucidating the associations between the bioactivities and structural characteristics(e.g., molecular weight and the presence of specific amino acids within sequences and compositions) of FBPs. We also discuss in silico approaches for FBP screening and their limitations. Finally, we summarize recent advancements in formulation techniques to improve the bioavailability of FBPs in the food industry, thereby contributing to healthcare applications.更多还原